𝔖 Bobbio Scriptorium

✦ LIBER ✦

Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences

✍ Scribed by Jean Deslauriers; Jocelyn Grégoire; Louis F Jacques; Michel Piraux; Liu Guojin; Yves Lacasse

Book ID: 116259112
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 128 KB
Volume: 77
Category: Article
ISSN: 0003-4975
DOI: 10.1016/j.athoracsur.2003.07.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Morbidity, Survival, and Site of Recurre

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small Cell Lung Cancer

✍ Didier Lardinois; Hans Suter; Hassan Hakki; Valentin Rousson; Daniel Betticher; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 274 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Once-daily radiotherapy to ≥59.4 Gy vers

Once-daily radiotherapy to ≥59.4 Gy versus twice-daily radiotherapy to ≥45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes

✍ John M. Watkins; John A. Fortney; Amy E. Wahlquist; Keisuke Shirai; Elizabeth Ga 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 257 KB

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS C

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

✍ MJ Nuijten; C Holmberg; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB